Management of sexually transmitted diseases is facilitated by having antimicrobial agents with activity against all of the major genital pathogens. Newer quinolones show promise of being active against Neisseria gonorrhoeae and Chiamydia trachomatis. Two quinolones, difloxacin (A-56619) and A-56620, and an oral cephalosporin, cefixime (CL 284,635; FK 027), were evaluated in vitro. All three were highly active against 400 isolates of N. gonorrhoeae, including penicillinase-producing N. gonorrhoeae, N. gonorrhoeae with chromosomally mediated resistance, and isolates with penicillin MICs of <1 ,ug/ml. Susceptibilities to one antimicrobial agent were usually strongly correlated with susceptibilities to the other antimicrobial agents evaluated, but isolates with increasing resistance to beta-lactams were least likely to show increasing resistance to quinolones. Difloxacin and, to a lesser extent, A-56620 were active against all 10 strains of C. trachomatis, and both had moderate activity against over 200 strains of Gardnerella vaginalis. Based on in vitro activity, difloxacin and A-56620 merit in vivo assessment for management of both C. trachomatis and N. gonorrhoeae infections, and cefixime shows considerable promise for treatment of N. gonorrhoeae infections.
Management of sexually transmitted syndromes is facilitated by having antimicrobial agents active against all of the major genital pathogens. Newer quinolones, especially ciprofloxacin and ofloxacin, show promise of having broad in vitro activity against many genital bacterial pathogens, including activity against penicillin-susceptible and penicillinresistant strains of Neisseria gonorrhoeae (1, 9, 10) and Chlamydia trachomatis (1, 2, 6, 7; R. J. Van Roosbroeck, D. R. Provinciael, and D. L. Van Caekenberghe, Letter, Br. J. Vener. Dis. 60:350, 1984) . Data on the activity of newer quinolones against Gardnerella vaginalis is limited (8) . In this study, two new quinolones, difloxacin hydrochloride (A-56619) and A-56620, were evaluated for in vitro activity against N. gonorrhoeae, C. trachomatis, and G. vaginalis, and a new oral cephalosporin, cefixime (CL 284,635; FK 027), was evaluated for in vitro activity against N. gonorrhoeae and C. trachomatis.
MATERIALS AND METHODS
Most of the isolates of N. gonorrhoeae used were obtained from men and women who were patients at the Sexually Transmitted Disease Clinic in the Vancouver Provincial Health Building from June 1982 to June 1984. Also studied were additional isolates of N. gonorrhoeae from all over British Columbia that were penicillin producing or showed zones of inhibition of 19 mm or less around a 10-U penicillin disk applied to chocolate agar (GC medium base, 1% hemoglobin, 1% defined GC supplement) (Alpkem-Western Ltd. tation, or both. Ten or more colonies were subcultured, and a modification of the iodometric paper strip was used to screen for beta-lactamase activity (8) . The presence of beta-lactamase activity in isolates positive by the iodometric test was confirmed with chromogenic cephalosporin (nitrocefin; Glaxo Pharmaceuticals, Ltd., Greenford, United Kingdom) (4). Isolates were stored at -70°C in glycerol citrate. In total, 250 isolates with penicillin MICs of <1 ,ug/ml, 50 isolates with penicillin MICs of 1 to 4 ,ug/ml that were not beta-lactamase producing (having chromosomally mediated resistance to N. gonorrhoeae [CMRNG] ), and 100 beta-lactamase-producing strains of N. gonorrhoeae (PPNG) were studied. Isolates were tested by standard agar dilution techniques (4) Table 3 indicates that MICs with A-56620 were least correlated with the beta-lactams but had similar correlations to tetracycline and difloxacin, with the exception that for isolates with penicillin MICs of <1 ,ug/ml the association was weak between A-56620 and tetracycline but strong between A-56620 and difloxacin.
The results against C. trachomatis are shown in Table 4 . In general, the MIC and MBC results were virtually identical for each antimicrobial agent. Overall, tetracycline was the most active compound, being approximately 1 dilution more active than difloxacin. A-56620 and ofloxacin had similar activities but were less active than difloxacin. Cefixime had essentially no activity against C. trachomatis.
The results against G. vaginalis are shown in Table 5 . Not all isolates survived for triplicate analyses against all antimicrobial agents. For isolates that survived, the most active compound on a weight basis was ampicillin. Difloxacin and A-56620 were next most active and produced virtually identical results. Metronidazole was considerably less active on a weight basis. b Lowest concentration at which no inclusions were detected when cultures were passed to new monolayers at 72 h, reincubated for 72 h, and stained.
DISCUSSION
Compared with other published studies, A-56620 appeared to have activity against N. gonorrhoeae similar to that of other very active new quinolones (1, 9, 10; P. J. Rettig, P. A. Haddad, R. K. Scribner, and M. I. Marks, Program Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 576, 1985). For both difloxacin and A-56620, the level of activity indicated that they may be clinically useful. Cefixime was highly active against N. gonorrhoeae with activity similar to that of ceftriaxone. Depending on bioavailability and pharmacokinetics in vivo, it could be the oral equivalent of parenterally administered ceftriaxone. Preliminary results of using oral cefixime for treatment of uncomplicated urethral N. gonorrhoeae infection in men appear promising (W. R. Bowie, unpublished data).
The pattern of correlations among the in vivo activities of different antimicrobial agents against N. gonorrhoeae may have relevance in vivo. For the newer agents, MICs to CMRNG were the highest. Furthermore, increasing resistance to one beta-lactam correlated highly with increasing resistance to other beta-lactams. In the past, independent of plasmid-mediated resistance to penicillins, isolates of N. gonorrhoeae have become increasingly more resistant to penicillin (11) . This resulted in the need for increasingly high This study showed that, like ofloxacin and ciprofloxacin, difloxacin and A-56620 had considerable in vitro activity against all strains of N. gonorrhoeae, C. trachomatis, and, to a lesser extent, G. vaginalis. They merit in vivo evaluation, especially for the syndromes of urethritis and cervicitis and their complications. On the basis of these data, difloxacin may be more clinically useful than A-56620 because of its greater activity against C. trachomatis. However, the ultimate decision will depend on pharmacokinetic and tolerance data. Cefixime lacks useful activity against C. trachomatis but could be a very effective single-dose oral treatment for N. gonorrhoeae infections.
